Skip to main content
Kane Biotech Inc. logo

Kane Biotech Inc. — Investor Relations & Filings

Ticker · KNE ISIN · CA4838092084 TSXV Manufacturing
Open in API
Filings indexed 582 across all filing types
Latest filing 2023-05-25 Regulatory Filings
Country CA Canada
Listing TSXV KNE

About Kane Biotech Inc.

https://kanebiotech.com/

Kane Biotech Inc. is a biotechnology company engaged in the research, development, and commercialization of proprietary technologies designed to prevent and remove microbial biofilms, which are a major contributor to chronic infections and impaired healing. The company holds extensive intellectual property related to biofilm formation and dispersal mechanisms, utilizing proprietary technologies such as DispersinB® and coactiv+®. Its primary commercial focus is advanced wound care, where products like the revyve® Antimicrobial Wound Gel and Spray are designed to disrupt biofilms and promote healing. The product pipeline also includes surgical and dermatological applications for both human and animal health.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings
2023-05-25 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the upcoming release date of Kane Biotech's first quarter 2023 financial results and a conference call to discuss those results. It does not contain the actual financial results or detailed financial statements. The document is short (3912 characters) and primarily serves as an announcement of the earnings release and conference call. According to the rules, such announcements are classified as Earnings Release (ER) if they contain key highlights of financial results, but this document does not include any financial highlights, only the announcement of the release date and call. Therefore, it fits best as a Regulatory Filing (RNS) since it is a general regulatory announcement about the timing of the earnings release and conference call, without substantive financial data or analysis.
2023-05-18 English
Management information circular - English.pdf
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled 'Management Information Circular' and includes a 'Notice of Annual and Special Meeting of Shareholders' for Kane Biotech Inc. It details the solicitation of proxies, meeting logistics, voting procedures, record dates, and shareholder rights. The content is focused on providing information to shareholders about the upcoming annual and special meeting, including election of directors, appointment of auditors, and other meeting business. It does not contain financial statements or detailed financial performance data, nor is it a transcript or presentation. It is a formal communication to shareholders in advance of the meeting, consistent with a Proxy Solicitation & Information Statement.
2023-05-02 English
Notice of meeting - English.pdf
AGM Information Classification · 95% confidence The document is a Notice of Annual and Special Meeting of Shareholders for Kane Biotech Inc. It includes details about the meeting date, access methods, agenda items such as reviewing audited financial statements, electing directors, appointing auditors, and approving a share unit plan. It also references a Management Information Circular for more details and instructions for proxy submission. The document is short (3596 characters) and serves as a formal notice to shareholders about the meeting rather than the meeting materials or results themselves. This fits the definition of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting, or more specifically, the notice of the AGM. Since it is a notice of the meeting, it is classified as AGM Information (AGM-R).
2023-05-02 English
Form of proxy - English.pdf
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a proxy form for the Annual and Special Meeting of shareholders of Kane Biotech Inc. It includes instructions for appointing a proxyholder to vote on behalf of shareholders at the meeting, details on how to vote, and information about the meeting date and agenda items such as election of directors and approval of a share unit plan. This type of document is typically distributed to shareholders to solicit their votes and is not the actual meeting materials or report itself. It is related to the Annual General Meeting but is not the AGM presentation or materials. Therefore, it fits best under the category of Proxy Solicitation & Information Statement (PSI). The document length and content confirm it is not a brief announcement or a full report but a proxy solicitation form.
2023-05-02 English
Report of exempt distribution excluding schedule 1 of Form 5.PDF
Regulatory Filings
2023-04-26 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.